On the sidelines of the Sixth Annual Forum of the General Authority for Healthcare—held this year under the patronage and in the presence of the Prime Minister, and themed “From Vision to Expansion”—the New Administrative Capital witnessed the signing of a Memorandum of Understanding between Novo Nordisk and the General Authority for Healthcare.
The agreement aims to strengthen the capabilities of medical teams involved in the awareness, diagnosis, and treatment of patients with hemophilia, particularly with the availability of a new generation of safe and effective advanced therapies that support improved care for people living with the condition.
This collaboration comes in line with the Authority’s commitment to enhancing early detection, accurate diagnosis, specialized care, and treatment pathways for rare genetic diseases. It also supports ongoing national efforts to improve services for patients with bleeding disorders—including hemophilia—through the implementation of the latest treatment protocols.
The signing ceremony was attended by Prof. Dr. Ahmed El-Sobky, Chairman of the General Authority for Healthcare and General Supervisor of the Universal Health Insurance Project, Prof. Dr. Amir El-Telwany, Executive Director of the General Authority for Healthcare, and Dr. Ayman Hassan, Vice President, Chairman & General Manager of Novo Nordisk Egypt and Libya.
Under this MoU, both parties will work to enhance the skills of healthcare professionals through a series of clinical training programs for all specialties involved in diagnosing and managing hemophilia. The agreement also includes expanding continuing medical education programs for pharmacists, nurses, and health educators, as well as updating treatment protocols to ensure that patients receive the highest level of care under the umbrella of the Universal Health Insurance system.
During his remarks at the signing, Dr. Ayman Hassan said:
“We are always pleased to partner with the General Authority for Healthcare in supporting the state’s efforts to improve care for people living with hemophilia. Collaboration between the public and private sectors has become a strategic necessity to ensure patients have access to the latest therapies, especially given the rapid advancements in this field.”
He added that Novo Nordisk’s commitment extends beyond providing medication, to building the scientific capabilities of medical teams and supporting the adoption of innovative solutions that improve patients’ quality of life.
“We reaffirm our dedication to working hand in hand with all our partners, in alignment with the directives of the political leadership and the Ministry of Health and Population in the New Republic, which continues to place strong emphasis on advancing care for rare diseases.”, he said.
In closing, Dr. Ayman Hassan, General Manager of Novo Nordisk Egypt and Libya, expressed his appreciation to Prof. Dr. Ahmed El-Sobky and Egypt Healthcare Authority for their continuous efforts to deliver high-quality healthcare that makes a meaningful difference in the future of patient care across Egypt.
